Dr. Abou-Alfa on Trial of MEK162 in Advanced Biliary Cancer

Video

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the trial of MEK162 in combination with gemcitabine and cisplatin in patients with untreated advanced biliary cancer.

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the trial of MEK162 in combination with gemcitabine and cisplatin in patients with untreated advanced biliary cancer.

This single arm, non-randomized, phase I/II study evaluated MEK162—an oral, selective small molecule inhibitor of MEK1/2—twice daily for 21 days with gemcitabine and cisplatin infusions on days 8 and 15.

This was based on preclinical data that showed that a certain cycling between gemcitabine, cisplatin, and the MEK inhibitor may allow the MEK to target the cells at their prime, says Abou-Alfa.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD